Abstract 2693: MDR1 and ERCC1 expression predict outcome in patients with locally advanced bladder cancer and adjuvant chemotherapy
Andreas-Claudius Hoffmann(University of Southern California), Arndt Hartmann(Universitätsklinikum Erlangen), Kathleen D. Danenberg(University of Southern California), Simone Bertz(Friedrich-Alexander-Universität Erlangen-Nürnberg), Robert Stöhr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Peter J. Wild(Goethe University Frankfurt), Peter V. Danenberg(University of Southern California), Martin Schüler(German Cancer Research Center)
Cited by 2
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
|Nature Methods|2014|2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k